A Non-Profit Works to Advance a DMD Gene Therapy

Frederic Revah, CEO of Genethon, discusses Duchenne muscular dystrophy, the organization’s efforts to complete clinical development of its gene therapy for the condition, and how it might commercialize the treatment.